Pollack Alan, Horwitz Eric M, Movsas Ben
Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA.
Semin Radiat Oncol. 2003 Apr;13(2):121-9. doi: 10.1053/srao.2003.50011.
Prostate cancer with pathologically documented regional lymph node positive disease has been associated with a dismal prognosis in the past. Clinical and/or biochemical progression is evident within 5 years in over 50% treated with external-beam radiotherapy (EBRT) alone, radical prostatectomy (RP) alone, or androgen deprivation (AD) alone. By 10 years after treatment, greater than 75% progress and over half succumb to prostate cancer. In contrast, the results with the combination of EBRT + AD or RP + AD have been very promising. Ten-year biochemical progression and overall survival rates are roughly 20% and 70%, respectively, for patients with subclinical lymph node involvement. Patients with a 10-year life expectancy should be treated aggressively with long-term AD combined with either EBRT or RP.
过去，病理证实有区域淋巴结阳性疾病的前列腺癌预后不佳。单独接受外照射放疗（EBRT）、根治性前列腺切除术（RP）或单独雄激素剥夺（AD）治疗的患者中，超过50%在5年内会出现临床和/或生化进展。治疗后10年，超过75%的患者病情进展，超过一半的患者死于前列腺癌。相比之下，EBRT + AD或RP + AD联合治疗的效果非常有前景。对于亚临床淋巴结受累的患者，10年生化进展率和总生存率分别约为20%和70%。预期寿命为10年的患者应积极接受长期AD联合EBRT或RP治疗。
